drugset / Trial / NCT04555811
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Phase 1
Completed
7 enrolled
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
Timeline
- Start
- 2020-09-22
- Primary completion
- 2023-02-08
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT596 | Cell therapy | 3e+07 cells | — |
| Subject | FT596 | Cell therapy | 9e+07 cells | — |
| Subject | FT596 | Cell therapy | 3e+08 cells | — |
| Subject | FT596 | Cell therapy | 9e+08 cells | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |